U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA (finerenone) to Treat Adults With Chronic Kidney Disease Without Diabetes
October 09, 2026
October 09, 2026
WHIPPANY, New Jersey, Oct. 9 (TNSjou) [Category: BizPharmaceuticals] -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, posted the following news:
* * *
October 9, 2026
U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA(R) (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
* The supplemental New Drug Application (sNDA) was supported b . . .
* * *
October 9, 2026
U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA(R) (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
* The supplemental New Drug Application (sNDA) was supported b . . .